Noradrenergic depletion increases inflammatory responses in brain: effects on IκB and HSP70 expression
The DOI matches its Crossref record; 13 of the 13 references it cites were found in a registry or an index.
Abstract
The inflammatory responses in many cell types are reduced by noradrenaline (NA) binding to β‐adrenergic receptors. We previously demonstrated that cortical inflammatory responses to aggregated amyloid beta (Aβ) are increased if NA levels were first depleted by lesioning locus ceruleus (LC) noradrenergic neurons, which replicates the loss of LC occurring in Alzheimer's disease. To examine the molecular basis for increased responses, we used the selective neurotoxin DSP4 to lesion the LC, and then examined levels of putative anti‐inflammatory molecules. Inflammatory responses were achieved by injection of aggregated Aβ1–42 peptide and IL‐1β into frontal cortex, which induced neuronal inducible nitric oxide synthase (iNOS) and microglial IL‐1β expression. DSP4‐treatment reduced basal levels of nuclear factor kappa B (NF‐κB) inhibitory IκB proteins, and of heat shock protein (HSP)70. Inflammatory responses were prevented by co‐injection (ibuprofen or ciglitzaone) or oral administration (pioglitazone) of peroxisome proliferator‐activated receptor gamma (PPARγ) agonists. Treatment with PPARγ agonists restored IκBα, IκBβ, and HSP70 levels to values equal or above those observed in control animals, and reduced activation of cortical NF‐κB. These results suggest that noradrenergic depletion reduces levels of anti‐inflammatory molecules which normally limit cortical responses to Aβ, and that PPARγ agonists can reverse that effect. These findings suggest one mechanism by which PPARγ agonists could provide benefit in neurological diseases having an inflammatory component.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Inflammation and Alzheimer’s disease
Akiyama, H. (2000) · Neurobiology of Aging · doi:10.1016/s0197-4580(00)00124-x · Cited by 4,514
The PPARs: From Orphan Receptors to Drug Discovery
Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R. (2000) · Journal of Medicinal Chemistry · doi:10.1021/jm990554g · Cited by 1,816
Risk of Alzheimer's disease and duration of NSAID use
Stewart, W. F., Kawas, C., Corrada, M., & Metter, E. J. (1997) · Neurology · doi:10.1212/wnl.48.3.626 · Cited by 1,132 · cited 1×
“There are compelling epidemiological data demonstrating that a subset of NSAIDs provide protection in AD (Rogers et al. 1993; Stewart et al. 1997), and long-term use is accompanied by significant reduction in activated microglia (Mackenzie and Munoz 2001).”
BackgroundLehmann, J. M., Lenhard, J. M., Oliver, B. B., Ringold, G. M., & Kliewer, S. A. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.6.3406 · Cited by 1,110 · cited 7×
“The ability of PPARc agonists (including NSAIDs) to restore IjB and HSP70 levels may therefore help account for their therapeutic benefits in AD.”
BackgroundInfluentialCombs, C. K., Karlo, J. C., Kao, S.-C., & Landreth, G. E. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-04-01179.2001 · Cited by 721
Self-citationCombs, C. K., Johnson, D. E., Karlo, J. C., Cannady, S. B., & Landreth, G. E. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-02-00558.2000 · Cited by 483
Self-citationMicroglia and inflammatory mechanisms in the clearance of amyloid β peptide
Rogers, J., Strohmeyer, R., Kovelowski, C. J., & Li, R. (2002) · Glia · doi:10.1002/glia.10153 · Cited by 381
The role of PPARs in inflammation and immunity
Clark, R. B. (2002) · Journal of Leukocyte Biology · doi:10.1189/jlb.71.3.388 · Cited by 337
Rogers, J., & Lue, L.-F. (2001) · Neurochemistry International · doi:10.1016/s0197-0186(01)00040-7 · Cited by 236
Bernardo, A., Levi, G., & Minghetti, L. (2000) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.2000.00110.x · Cited by 222 · cited 1×
“Suppression of Ab/IL-1b effects by PPARc agonists PPARc agonists reduce neuronal and glial inflammatory gene expression (Bernardo et al. 2000; Heneka et al. 2000a; 2003 International Society for Neurochemistry, J. Neurochem.”
Background
Cited by
Inflammatory processes in Alzheimer's disease
Heneka, M. T., & O'Banion, M. K. (2007) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2006.11.017 · Cited by 782
Self-citationNeuroinflammatory processes in Alzheimer’s disease
Heneka, M. T., O’Banion, M. K., Terwel, D., & Kummer, M. P. (2010) · Journal of Neural Transmission · doi:10.1007/s00702-010-0438-z · Cited by 433
“Interestingly, iNOS expression was completely restricted to microglial cells in controls, whereas NA depleted animals showed widespread iNOS expression in pyramidal neurons (Heneka et al. 2002; Heneka et al. 2003), a phenomenon previously reported in AD brains (Heneka and Feinstein 2001).”
BackgroundResultSelf-citationNoradrenergic mechanisms in neurodegenerative diseases: a theory
Marien, M. R., Colpaert, F. C., & Rosenquist, A. C. (2004) · Brain Research Reviews · doi:10.1016/j.brainresrev.2004.02.002 · Cited by 414
Ren, M., Leng, Y., Jeong, M., Leeds, P. R., & Chuang, D. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02406.x · Cited by 378
Role of inflammation in neurodegenerative diseases
Minghetti, L. (2005) · Current Opinion in Neurology · doi:10.1097/01.wco.0000169752.54191.97 · Cited by 335
Metadata
- Authors
- Heneka, M. T., Gavrilyuk, V., Landreth, G. E., O'Banion, M. K., Weinberg, G., & Feinstein, D. L.
- Venue
- Journal of Neurochemistry
- Publisher
- Wiley
- Published
- 2003-04
- Volume
- 85
- Issue
- 2
- Pages
- 387-398
- ISSN
- 0022-3042 (ISSN-L)
- 1471-4159
- OpenAlex
- W1585801143
- Cited by
- 142
- References
- 13
- FWCI
- 7.13
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Noradrenergic depletion increases inflammatory responses in brain: effects on IκB and HSP70 expression. https://app.cochat.ai/papers/10.1046/j.1471-4159.2003.01694.x
- The paper
- Heneka, M. T., Gavrilyuk, V., Landreth, G. E., O'Banion, M. K., Weinberg, G., & Feinstein, D. L. (2003). Noradrenergic depletion increases inflammatory responses in brain: effects on IκB and HSP70 expression. Journal of Neurochemistry. https://doi.org/10.1046/j.1471-4159.2003.01694.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.